New drug cocktail shows promise for rare protein disease
NCT ID NCT03283917
First seen Mar 04, 2026 · Last updated Jun 12, 2026 · Updated 17 times
Summary
This early-stage study tests the safety and best dose of a three-drug combination (daratumumab, ixazomib, and dexamethasone) for people with AL amyloidosis, a rare disease where abnormal proteins build up in organs. The trial includes 21 participants with newly diagnosed or returning disease. The goal is to find the safest dose and see how well the drugs control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PRIMARY AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.